Across America over the past 25 years, millions of people – who might not otherwise receive proper medical treatment due to its cost – have come to depend on care at facilities participating in the 340B Drug Discount Program. Established by Congress in 1992 and signed into law by President Bush, the 340B program allows more than 2,100 nonprofit health care providers serving low-income and uninsured populations to buy outpatient prescription drugs at a discount. Under 340B, pharmaceutical manufacturers who choose to participate in Medicaid agree to provide outpatient drugs to this select group of nonprofit health care providers at reduced prices. Expanding this successful program would help make America great again, yet unfortunately and predictably, this vital drug discount program is currently under attack in the big swamp called Washington, DC. Why is this good program under attack? Because special interests in the swamp want participating non-profit hospitals to pay higher drug prices to further grow the pharmaceutical companies’ already-high profits – currently about 25 percent. To make this happen, they are using the classic, old-school Washington playbook: spread fake news, fly under a high-minded banner of “reform,” and spend lots of money on Congressional campaign contributions, highly-paid lobbyists, consultants and bogus reports. Sound familiar?

“ The choice for Members of Congress and President Trump is clear: they can fall for the fake news disseminated by the Washington special interests and submit to them, or, they can drain the swamp and protect the American people. ”





Here is the real, not fake, news about the 340B drug discount program. First, the program is free for taxpayers and the federal government. Because drug companies voluntarily offer these drug discounts to certain non-profit health providers, the program provides billions of dollars of cost savings on drugs at no cost to taxpayers. Second, the program does exactly what it was intended to do: benefit millions of patients by providing voluntary drug discounts to a select group of nonprofit health care providers who provide significant uncompensated health care. Despite this truth, special interests in the swamp keep repeating the lie that the program was intended to allow patients to acquire drugs at discounted prices.



